Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00297258
First received: February 24, 2006
Last updated: September 4, 2014
Last verified: August 2014
  Purpose

The purpose of this study is to evaluate the activity and tolerability of pazopanib in subjects with advanced and/or metastatic soft tissue sarcoma who have relapsed following standard therapies or for whom no standard therapy exists and to characterize the pharmacokinetics of pazopanib in this subject population.


Condition Intervention Phase
Sarcoma, Soft Tissue
Drug: pazopanib
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of GW786034 in Patients With Relapsed or Refractory Soft Tissue Sarcoma

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Progression Free Survival at Week 12 [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
    Progression free survival at week 12 is the number of participants who had a complete response (CR, all detectable tumor had disappeared) or a partial response (PR, a >=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum) or stable disease (SD, no change) 12 weeks from start of therapy, per response evaluation criteria in solid tumors (RECIST v1.0). Clinical progression is progression of disease without documented radiological evidence. Progressive disease (PD), a >=20% increase in target lesions.


Secondary Outcome Measures:
  • Overall Survival [ Time Frame: Start of therapy until death (up to approximately 5 years) ] [ Designated as safety issue: No ]
    Overall survival is defined as the time from start of therapy until death. Participants who were still alive at the time of analysis were censored.

  • Progression Free Survival [ Time Frame: Start of therapy until progression (up to approximately 5 years) ] [ Designated as safety issue: No ]
    Progression free survival is defined as the interval between the start of treatment and the earliest date of disease progression or death due to any cause. Assessments of progression were made by the investigator.

  • Overall Response [ Time Frame: Baseline until either response or progression (up to approximately 5 years) ] [ Designated as safety issue: No ]
    Overall response is the number of participants who had a best outcome of a complete response (CR, all detectable tumor had disappeared) or a partial response (PR, a >=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum) per response evaluation criteria in solid tumors (RECIST v1.0) at some point during the study. Progressive disease (PD), a >=20% increase in target lesions. Clinical progression is progression of disease without documented radiological evidence.


Enrollment: 148
Study Start Date: November 2005
Study Completion Date: December 2012
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: pazopanib
    oral tablet
    Other Name: GW786034
  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histological evidence of high or intermediate grade malignant soft tissue sarcoma, or cytological evidence in case of presence of multiple metastases. List of eligible and ineligible tumours are included in the protocol.
  • Formalin fixed paraffin embedded tumour blocks and representative H/E (haematoxylin/eosin) slides must be available for histological central review. Histological central review is not required before treatment start but is mandatory within 3 months of registration. Local histopathological diagnosis will be accepted for entry into the study.
  • Presence of measurable disease (according to RECIST criteria).
  • Relapsed or refractory disease incurable by surgery or radiotherapy.
  • Evidence of objective progression within the last 6 months (RECIST) documented by measurements of disease,
  • Patients must either not be eligible for chemotherapy (for instance because of age, or because of a biological condition, or because of patient-refusal) or must have received no more than one combination or two single agents chemotherapy regimen for advanced disease; (neo) adjuvant therapy is not counted towards this requirement.
  • At least 18 years of age
  • WHO performance status 0 or 1
  • Adequate bone marrow function
  • Adequate hepatic function
  • Adequate renal function
  • PT / PTT less than 1.2 x UNL.
  • LVEF above the lower limit of normal for the institution, based on ECHO or MUGA
  • Able to swallow and retain oral medication
  • Women should not be of childbearing potential and agree to use contraceptive methods (Oral contraceptives are not allowed).
  • Absence of any serious and/or unstable pre-existing medical, psychiatric or other condition (including lab abnormality) that could interfere with patient safety or obtaining informed consent.
  • Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be assessed with the patient before registration in the trial.
  • Written informed consent is given according to ICH/GCP, and national/local regulations before patient registration/randomization.

Exclusion Criteria:

  • history of leptomeningeal or brain metastases
  • history of malignancies other than sarcoma (except for basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast, or the patient has been free of any other malignancies for greater than 3 years).
  • Class II, III or IV heart failure (NYHA classification). A patient who has a history of class II heart failure and is asymptomatic on treatment may be considered eligible.
  • Arterial or venous thrombosis, myocardial infarction, unstable angina, cardiac angioplasty or stenting within the last 3 months
  • Uncontrolled or poorly controlled hypertension. Initiation or adjustment of BP medications is permitted prior to study entry, provided that patient has 3 consecutive BP readings less than 150 / 90 mm Hg each separated by a minimum of 24 hrs. These readings need to be collected prior to registration in the study.
  • Women of childbearing potential, who are pregnant (negative serum pregnancy test at entry) or lactating.
  • Therapeutic dose warfarin. Low molecular weight heparin and prophylactic low dose warfarin are permitted. PT/INR and PPT must meet the above inclusion criteria.
  • Concurrent therapy with any specifically prohibited medication or requirement for using any of these medications during treatment with pazopanib
  • Major surgery, hormonal therapy (other than replacement), chemotherapy or radiotherapy, immunotherapy or other investigational agent within the last 28 days and/or not recovered from prior therapy within the last 28 days. Use of erythropoietin is considered supportive care and is permitted. The patient should have recovered from prior surgery and have no open wounds.
  • History of malabsorption syndrome, disease significantly affecting gastrointestinal function or major resection of the stomach or small bowel that could affect absorption, distribution, metabolism or excretion of study drugs. No unresolved bowel obstruction or diarrhea.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00297258

Locations
Belgium
GSK Investigational Site
Bruxelles, Belgium, 1000
GSK Investigational Site
Leuven, Belgium, 3000
France
GSK Investigational Site
Lyon cedex 03, France, 69437
GSK Investigational Site
Marseille, France, 13385
GSK Investigational Site
Paris Cedex 05, France, 75248
GSK Investigational Site
Villejuif, France, 94805
Hungary
GSK Investigational Site
Budapest, Hungary, 01135
Netherlands
GSK Investigational Site
Groningen, Netherlands, 9713 GZ
GSK Investigational Site
Leiden, Netherlands, 2300 RC
GSK Investigational Site
Rotterdam, Netherlands, 3075 EA
United Kingdom
GSK Investigational Site
Manchester, Lancashire, United Kingdom, M20 4BX
GSK Investigational Site
Glasgow, United Kingdom, G11 6NT
GSK Investigational Site
Leeds, United Kingdom, LS9 7TF
GSK Investigational Site
London, United Kingdom, SW3 6JJ
GSK Investigational Site
Newcastle upon Tyne, United Kingdom, NE7 7DN
GSK Investigational Site
Sheffield, United Kingdom, S10 2SJ
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00297258     History of Changes
Obsolete Identifiers: NCT00293449
Other Study ID Numbers: VEG20002
Study First Received: February 24, 2006
Results First Received: December 2, 2009
Last Updated: September 4, 2014
Health Authority: European Union: European Medicines Agency

Keywords provided by GlaxoSmithKline:
Sarcoma
Synovial sarcoma
Pazopanib(GW786034)
Adipocytic tumors
Leiomyosarcoma
Phase II

Additional relevant MeSH terms:
Sarcoma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Connective and Soft Tissue

ClinicalTrials.gov processed this record on October 23, 2014